Discovery of a kinome signature predicting sensitivity and resistance to RAF-MAPK pathway inhibitors in melanoma

被引：0
|
作者：
Hilhorst, Riet
Krayem, Mohammed
Van den Berg, Adrienne
Journe, Fabrice
Hovestad-Bijl, Liesbeth
Van den Hooven, Tim
de Wijn, Rik
Aftimos, Philippe
Ghanem, Ghanem
Ruijtenbeek, Rob
机构：
来源：
CANCER RESEARCH | 2017年 / 77卷
关键词：
D O I：
10.1158/1538-7445.AM2017-3163
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3163
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth
    Bhargava, Ajay
    Pelech, Steven
    Ben Woodard
    Kerwin, John
    Maherali, Nimet
    ELIFE, 2016, 5
  • [22] In Vivo MAPK Reporting Reveals the Heterogeneity in Tumoral Selection of Resistance to RAF Inhibitors
    Basile, Kevin J.
    Abel, Ethan V.
    Dadpey, Neda
    Hartsough, Edward J.
    Fortina, Paolo
    Aplin, Andrew E.
    CANCER RESEARCH, 2013, 73 (23) : 7101 - 7110
  • [23] Modeling the evolution of resistance to RAF inhibitors in clinically relevant melanoma models
    Das Thakur, Meghna
    Salangsang, Fernando
    Pryer, Nancy
    Stuart, Darrin
    McMahon, Martin
    CANCER RESEARCH, 2012, 72
  • [24] Kinome Profiling to Predict Sensitivity to MAPK Inhibition in Melanoma and to Provide New Insights into Intrinsic and Acquired Mechanism of Resistance (vol 12, 512, 2020)
    Krayem, Mohammad
    Aftimos, Philippe
    Najem, Ahmad
    van den Hooven, Tim
    van den Berg, Adrienne
    Hovestad-Bijl, Liesbeth
    de Wijn, Rik
    Hilhorst, Riet
    Ruijtenbeek, Rob
    Sabbah, Malak
    Kerger, Joseph
    Awada, Ahmad
    Journe, Fabrice
    Ghanem, Ghanem E.
    CANCERS, 2024, 16 (14)
  • [25] RAF signaling and SHOC2 mediate mutant NRAS acquired resistance to RAF inhibitors in melanoma
    Kugel, Curtis H.
    CANCER RESEARCH, 2012, 72
  • [26] Dependence on PI3K and RAS-RAF pathways drives the activity of the combination of everolimus (RAD001) and RAF265, a novel inhibitor of the RAF-MAPK pathway, invitro and in vivo
    Mordant, Pierre
    Loriot, Yohann
    Leteur, Celine
    Tao, Yungan
    Bourhis, Jean
    Soria, Jean-Charles
    Deutsch, Eric
    CANCER RESEARCH, 2009, 69
  • [27] Melanoma metabolism contributes to the cellular responses to MAPK/ERK pathway inhibitors
    Marchetti, Philippe
    Trinh, Anne
    Khamari, Raeeka
    Kluza, Jerome
    BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 2018, 1862 (04): : 999 - 1005
  • [28] A Novel Mitochondrial Inhibitor Blocks MAPK Pathway and Overcomes MAPK Inhibitor Resistance in Melanoma
    Gopal, Y. N. Vashisht
    Gammon, Seth
    Prasad, Rishika
    Knighton, Barbara
    Pisaneschi, Federica
    Roszik, Jason
    Feng, Ningping
    Johnson, Sarah
    Pramanik, Snigdha
    Sudderth, Jessica
    Sui, Dawen
    Hudgens, Courtney
    Fischer, Grant M.
    Deng, Wanleng
    Reuben, Alexandre
    Peng, Weiyi
    Wang, Jian
    McQuade, Jennifer L.
    Tetzlaff, Michael T.
    Di Francesco, Maria E.
    Marszalek, Joe
    Piwnica-Worms, David
    DeBerardinis, Ralph J.
    Davies, Michael A.
    CLINICAL CANCER RESEARCH, 2019, 25 (21) : 6429 - 6442
  • [29] Role of IGF1R in mediating resistance to MAPK pathway inhibitors in BRAF-mutant melanoma
    Patel, Hima
    Mishra, Rosalin
    Broit, Natasa
    Yacoub, Nour
    Yuan, Long
    Alanazi, Samar
    Hayward, Nicholas
    Johansson, Peter
    Garrett, Joan T.
    CANCER RESEARCH, 2020, 80 (16)
  • [30] Metabolic modulation combined with mTOR pathway inhibition may overcame cutaneous melanoma resistance to MAPK inhibitors treatment
    Sampaio, C.
    Domingues, B.
    Soares, P.
    Lopes, J. M.
    Populo, H.
    EUROPEAN JOURNAL OF CANCER, 2020, 138 : S23 - S23
12345